期刊文献+

拉帕替尼类似物的合成及抗肿瘤活性研究 被引量:3

Synthesis and Antitumor Activity of New Lapatinib Derivatives
原文传递
导出
摘要 以N’-(2-氰基-4-碘苯基)-N,N-二甲基甲脒为原料,经过Dimroth重排反应、Suzuki偶联、还原氨化3步反应合成了4种新型的拉帕替尼类似物。借助NMR、IR和HRMS对反应中间体和目标化合物进行结构表征,并采用MTT法在SW480、A549和A431人肿瘤细胞上进行了这些化合物抗肿瘤活性的初步体外评价。结果表明,以上4种化合物均具有明显的抑制肿瘤细胞生长作用,特别是化合物5a对所试肿瘤细胞均表现出良好的生长抑制活性(IC50:5.78~13.38μmol/L),与临床使用的抗肿瘤药物拉帕替尼的活性(IC50:4.80~14.90μmol/L)相当。 Four new lapatinib derivatives were prepared using N’-( 2-cyano-4-iodophenyl)-N,N-dimethylformamidine as the starting material by Dimroth rearrangement,Suzuki coupling,reductive amination in turn. The structures of the reaction intermediates and target compounds were characterized with the NMR,IR and HRMS. The antitumor activities of these compounds on SW480,A549 and A431 tumor cells were tested preliminarily by the MTT method in vitro experiment. The results indicated that they had significant inhibition on the growth of tumor cells,especially compound 5a showed good growth inhibitory activity on all the test cells( IC50: 5. 78 ~ 13. 38μmol/L)which is similar as that of lapatinib( IC50: 4. 80 ~ 14. 90μmol/L).
出处 《化学通报》 CAS CSCD 北大核心 2016年第4期360-365,共6页 Chemistry
基金 国家自然科学基金项目(21272144)资助
关键词 拉帕替尼 抗肿瘤活性 合成 Lapatinib Anti-tumor activity Synthetic
  • 相关文献

参考文献16

二级参考文献117

  • 1任淑华,张林,王井伟,田海梅,曲平,张伟.靶向Her2/neu基因小干扰RNA对肺腺癌Calu-3细胞株药物敏感性的影响[J].中华结核和呼吸杂志,2006,29(1):35-38. 被引量:4
  • 2陈国良,耿春梅,刘湘永.白藜芦醇衍生物及类似物的研究进展[J].药学进展,2006,30(4):145-150. 被引量:15
  • 3李铭东,曹萌,吉民.盐酸埃洛替尼的合成[J].中国医药工业杂志,2007,38(4):257-259. 被引量:10
  • 4Hegde PS,Rusnak D,Bertiaux M,et al.Delineation of molecular mechanisms of sensitivity to Iapatinib in breast canner cell lines using global gene expression profiles[J].Mol Cancer Ther,2007,6 (5):1629-1640.
  • 5Ito Y,Tokudome N,Sugihara T,et al.Does lapstinib,a small-moleeule tyrosine kinase inhibitor,constitute a breakthrough in the treat ment of breast cancer[J].Breast Cancer,2007,14(2):156-162.
  • 6Medina PJ,C,oadin S.Lapatinib:a dual inhibitor of human epidermal growth factor receptor tyrosine kinases[J].Clin Ther,2008,30(8):1426-1447.
  • 7Lin NU,Diéras V,Paul D,et al.Muhi-eenter phase Ⅱ study of lapatinib in patients with brain metastuses from HER2-positive breast caneer[J].Clin Cancer Res,2009,15(4):1452 -1459.
  • 8Engnl RH,Kaklamani VG.HER2-positive breast cancer:current and future treatment stmtagies[J].Drugs,2007,67 (9):1329-1341.
  • 9Porters CC,Walshe JM,Rosing DR,et al.Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with[corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer[J].Clin Cancer Res,2009,14(9):2710 -2716.
  • 10Albanell J,Montagnt C,Jones ET,et al.A phase Ⅰ study of the safety and pharmacokinetics of the combination of pertuzumab (thuMab 2C4) and capeeitsbine in patients with advanced solid tumors[J].Clin Cancer Res,2008,14(9):2726 -2731.

共引文献57

同被引文献14

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部